Medtronic (MDT) CEO Omar Ishrak is flying the high of the medical device company’s Q2 earnings report, tweeting up a storm (for him). Ishrak, who normally dips in and out of Twitter with no more than a few tweets a week, has made at least seven posts about #MDTEarnings in two days. Here’s what the CEO has to say about Medtronic surpassing almost every revenue goal it set for its last reported quarter.
Thanks to Medtronic employees around the world who contribute to our Mission every day; proud of our results #MDTEarnings
— Omar Ishrak (@MedtronicCEO) November 19, 2013
Pleased to share FY14 Q2 earnings this morning; we’re performing at or better than the market in almost every business #MDTEarnings — Omar Ishrak (@MedtronicCEO) November 19, 2013
Our cadence of new products – most exciting since I’ve been at Medtronic; building on platform of execution #MDTEarnings — Omar Ishrak (@MedtronicCEO) November 19, 2013
Execution is offsetting pressure in dynamic envir; focus on areas we control: launching prods, managing cost & growing mkts #MDTEarnings — Omar Ishrak (@MedtronicCEO) November 19, 2013
^This is probably the most forward-looking tweet, as the others (below) reiterate what analysts have been advising the medtech industry to do for at least the last year.
New therapies, globalization & econ value will steadily improve position, strengthen & geog diversify bus. for reliable growth #MDTEarnings — Omar Ishrak (@MedtronicCEO) November 20, 2013
A Deep-dive Into Specialty Pharma
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
Collaborating w/ broader stakeholders & new business models; moving from accountable for product to an outcome #MDTEarnings — Omar Ishrak (@MedtronicCEO) November 20, 2013
UPDATE (One more tweet):
Continued progress in services & solutions to offer benefits to broader stakeholders, including gov’t, payers & hospitals #MDTEarnings
— Omar Ishrak (@MedtronicCEO) November 20, 2013
I’m not sure he’s going to make #MDTEarnings happen.
In fact, in May, Hugo Campos turned the hashtag around to say the earnings should support patient access.
@Bill_George@MedtronicCEO Nice indeed. Maybe Omar can put some of those #MDTEarnings toward giving patients access to their health data.
— Hugo Campos (@HugoOC) May 25, 2013
Follow MedCity News on Facebook and Twitter for more updates.
